Page last updated: 2024-12-08
nbd-5-acylcholine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
NBD-5-acylcholine: fluorescent analog of acetylcholine; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 194337 |
MeSH ID | M0071985 |
Synonyms (6)
Synonym |
---|
nbd-5-acylcholine |
70214-86-7 |
ethanaminium, n,n,n-trimethyl-2-((6-((7-nitro-4-benzofurazanyl)amino)-1-oxohexyl)oxy)- |
trimethyl-[2-[6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoyloxy]ethyl]azanium |
n-7-(4-nitrobenzo-2-oxo-1,3-diazole)-omega-aminohexanoic acid beta-(n-trimethylammonium)ethyl ester |
DTXSID50220478 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" To explain sigmoidal dose-response curves, a two-site model is already sufficient." | ( Interaction of cholinergic ligands with the purified acetylcholine receptor protein. I. Equilibrium binding studies. Maelicke, A; Prinz, H, 1983) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |